Echocardiography has advanced significantly since its first clinical use. The move towards more accurate imaging and quantification has driven this advancement. In this review, we will briefly focus on three distinct but important recent advances, three-dimensional (3D) echocardiography, contrast echocardiography and myocardial tissue imaging. The basic principles of these techniques will be discussed as well as current and future clinical applications.
3D echocardiography
The heart is a complex, moving, 3D shape and for many years operators of ultrasound have had to build up an image of the heart in their mind using a series of two-dimensional (2D) "cuts". Live 3D echocardiography is a novel technique for evaluation of cardiac abnormalities without any of the assumptions made in 2D imaging. Recent guidelines on the acquisition and display of 3D datasets have been published to attempt to standardise the clinical application of this advanced echocardiographic modality. 1 A 2D phased array transducer provides only one plane of imaging at a time whereas a 3D matrix array transducer functions in a similar way to a shower head, giving a 3D "shower" of ultrasound in both the lateral and elevation planes. The 2D imaging plane within the 3D dataset may therefore be "foreshortened" as the LV apex is captured within the data set. Post processing adjustments can then be made to obtain the true apex ( Figures  1 and 2 ) allowing for more accurate assessment of LV volumes and ejection fraction.
There are two types of 3D imaging; i) live 3D where a single beat volume can be acquired ii) multi-beat 3D; where the 3D dataset is acquired over multiple beats (usually from 2 to 7 beats). The advantage of a live 3D volume is that there is no "stitching" of beats together which may cause artifacts and misalignment of structures. In addition, single beat volume can be used in the presence of arrhythmias such as atrial fibrillation which are common in the cardiac patient population. The downside is that the spatial and temporal resolution is compromised and can reduce accuracy in quantification. A multi-beat acquisition gives a much higher frame rate and is often the only type of 3D dataset that can be analysed in dedicated 3D quantification software packages. Despite these limitations, 3D echocardiography has significant advantages over cardiac magnetic resonance imaging (MRI) and computed tomography (CT) in that it is relatively inexpensive, portable and can be used for patients with metal implants and claustrophobia.
Left ventricular assessment
Left ventricular mass, volumes and ejection fraction (EF) are important prognostic parameters 2-6 that are used for serial follow up of patients in various conditions including congestive cardiac failure, ischaemic heart disease, and valvular disease and for monitoring chemotherapy cardiac toxicity. Unfortunately, 2D echocardiography has limited test-retest reliability with regards to measuring LV parameters and has been reported to give a variation in EF between operators of as much as 11%. 7, 8 Cardiac MRI is considered the gold standard as it overcomes the geometrical assumptions made in 2D echocardiography; however the cost and availability of MRI makes it more difficult in a clinical setting. 3D echocardiography has a lower cost than MRI and has been found to have a high reproducibility in regards to LV volumes, EF and mass and is comparable to MRI. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] There is a high test-retest reliability of 3D LV volume and EF measurements 26 making it ideal for serial EF follow up, particularly when using a semi-automated border detection software which does not rely on geometric assumptions of a "normal" LV.
14,16,27,28 It also improves the detection of regional wall motion abnormalities compared with 2D imaging.
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Contrast imaging (discussed later) can also be used with 3D echocardiography to improve image quality and assist in assessment of EF and regional wall motion abnormalities. 30 Recently, 3D echocardiography has been used to determine LV dyssynchrony. [31] [32] [33] [34] [35] It has been found that a 3D derived dyssynchrony index can determine which chronic heart failure patients are more likely to respond to cardiac resynchronisation therapy. 36 Contraction wave mapping is also thought to assist in determining the area of latest activation and therefore the optimal position for lead placement. 37, 38 3D echocardiography may also be used in the assessment of right ventricular [39] [40] [41] [42] [43] and left atrial [44] [45] [46] [47] [48] [49] volumes and function but is beyond the scope of this review.
Valvular assessment:
As a 3D dataset can be cropped and displayed in any orientation, direct visualisation or "enface" views can be obtained (depending on image quality) of all four valves. The development of 3D transoesphageal echocardiography (TOE) has made 3D valvular assessment easier with superior resolution of images, particularly in mitral valve disease. The ability to display the mitral valve enface and in a surgical view (displayed as the surgeon would see the valve after opening up the left atrium) allows easier communication between cardiology and surgical teams (Figures 3 and 4) . Note the resolution differences between the transthoracic (TTE) and TOE images.
Both 3D TOE and TTE have been shown to improve the detection of mitral valve disease, particularly where complex pathology such as a cleft or prolapse at the commissural level exists. [50] [51] [52] [53] [54] The measurement of mitral valve area in mitral stenosis from 3D planimetry has a better correlation with invasively derived results than 2D alone [55] [56] [57] [58] [59] [60] [61] [62] ( Figure 5 ). Other cardiac valves can also be visualised and assessed using both 3D TTE and TOE. Estimation of aortic valve area in aortic stenosis via direct planimetry [63] [64] [65] [66] and continuity equation 67, 68 can be performed using 3D and has been shown to be superior to 2D assessment alone. Colour Doppler is also available using 3D; 69, 70 however single beat acquisition is not available in this mode due to poor temporal and spatial resolution. A 4 to 7 beat acquisition is required to obtain a 3D colour dataset and care must be taken to avoid "stitching" artifact. Quantification of both the vena contracta and the proximal isovelocity surface area (PISA) in mitral regurgitation has been shown to be more accurate and reproducible using 3D compared to 2D. [71] [72] [73] [74] The vena contracta in the assessment of aortic regurgitation can also be more accurately assessed with 3D echocardiography. 75, 76 
Other 3D uses
The same measurement package used for calculation of mitral valve area may also be used to size atrial septal defects prior to device closure and has been shown to be superior to 2D assessment alone 77 ( Figure 6 ). Another less heralded but very clinically useful feature of 3D technology is multi-plane imaging which allows a structure to be displayed in simultaneous orthogonal views. Not only does this make interrogation of structures such as mitral valve and left atrial appendage quicker and more accurate, it plays an important role in guiding interventions such as septal punctures ( Figure  7 ), septal defect closure devices (Figure 8) , [78] [79] [80] percutaneous valve repairs, 81 percutaneous repair of prosthetic mitral valve paravalvular regurgitation, [82] [83] [84] [85] balloon valvuloplasty 81 and placement of left atrial appendage occluder devices.
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Contrast echocardiography
Contrast echocardiography is an important arsenal in any echo laboratory in improving image quality. Its uptake into the Australian setting has been slow but has gained momentum since the introduction of second generation contrast agents. This technique has special relevance in Australia with increasing obesity and co-morbidities such as airway diseases making optimal imaging difficult in up to 10-15% of patients. 87 Contrast echo relies on different ultrasound properties exhibited by the contrast agents and human tissue enabling better delineation of the endocardium. Agitated saline injected into peripheral veins has long been used as a simple and readily available contrast agent to opacify right heart structures as well as identify intracardiac shunts and improve Doppler signals (i.e. tricuspid regurgitation). However, left heart contrast agents require that the microbubbles are small (4-5 μm) and resilient enough to pass through the pulmonary circulation. 87 Commercially available contrast agents are small microbubbles consisting of an inert gas encapsulated by a surface shell, often a lipid or polymer coat. When subjugated to ultrasound waves they oscillate (normal tissues don't), creating multiple frequencies that can create a stronger signal intensity in comparison to tissue which causes the blood pool to opacify hence improving endocardial definition. Furthermore, current ultrasound machines use various processes to suppress tissue signals while enhancing the signal from the contrast agents. 87 
Contrast safety
The Food and Drug Administration (FDA) and European licensing authority in the recent past have raised safety concerns based on a higher than usual incidence of deaths in critically ill patients who have undergone contrast echo. 88 However, subsequent studies using a larger numbers of patients have demonstrated conclusively that contrast is very safe. [87] [88] [89] The half life of contrast echo is short and it is excreted from the body through the lungs within a few minutes. Unlike other contrast agents used in imaging, echo contrast does not affect the kidneys and has a very low incidence of allergic reactions. The most common side-effects that patient may experience are minor and include flushing headache, nausea, chest or back pain. The only absolute contra-indication to contrast would include previous allergy to the agent and known intra-cardiac shunting.
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Administration of contrast All major ultrasound companies have a contrast package that can be purchased as an option. The mechanical index (the power of the ultrasound beam) needs to be reduced to avoid destroying the microbubbles and the focal zone should be lowered to the base of the heart (around the mitral valve level). The near field gain needs to be reduced as the contrast is particularly bright in the LV apex. The contrast agent is injected into a peripheral vein very slowly along with a saline flush or for sustained imaging. An infusion pump may be used. 87 Any remaining contrast is discarded. The agents have a six-month shelf life and needs to be refrigerated. The current American Society of Echocardiography (ASE) and European Association of Echocardiography (EAE) guidelines suggest that the use of contrast agents are indicated when greater than two of the 17 LV wall segments are poorly visualised 87 ( Figures 9 and 10 ). Currently there are no specific Australian guidelines available on the use of contrast agents in echocardiography.
If there is not enough contrast in the LV (noted as contrast "swirling" in the LV) you can either inject more contrast or reduce the mechanical index. If attenuation of the beam occurs you usually have to wait for some of the contrast to leave the LV or increase your mechanical index. 87 
Clinical indications
The most common use of contrast is to better assess LV function in patients whose images are suboptimal with normal harmonic imaging, known as LV opacification (LVO). [90] [91] [92] [93] [94] It can also be used for stress and dobutamine echocardiography [95] [96] [97] [98] to increase the number of wall segments visualised enabling greater accuracy in diagnosing coronary artery disease. It is also particularly useful in assessing for apical thrombus 99 which appears black in comparison to the white blood pool (Figure 11) . Rare conditions such as apical hypertrophy 100 can be distinguished from foreshortening using contrast ( Figure  12 ). Non-compaction cardiomyopathy which is characterised by deep recesses within the endocardium can also be highlighted by contrast echo. 101 Contrast can also be used to enhance the quality of Doppler signals and is particularly useful in difficult aortic stenosis cases. 102, 103 Assessment of myocardial perfusion can also be performed but its use for this purpose has not yet been approved by the FDA and therefore is still in the research and development phase.
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Myocardial tissue Imaging
One of the newer and exciting advances in echocardiography is the ability to use imaging techniques which are based on tissue Doppler or myocardial speckles to directly assess LV function and mechanics. These techniques unlike EF and visual estimation of LV function, which look at volume displacement, directly assess the mechanics of the myocardial tissue. They can measure the velocity of myocardial motion or the deformation (also known as strain). This technique is more commonly used to assess mitral annular velocities to assist in the determination of diastolic function. Tissue Doppler imaging (TDI) uses the same principle as pulsed wave Doppler except that it detects myocardial motion in relationship to the transducer rather than blood flow ( Figure  13 ). The best profile is obtained when the motion of the tissue is directly aligned to the ultrasound beam. Hence TDI is best suited for myocardial motion in the longitudinal plane using an apical window. This angle dependency of TDI is this techniques' greatest limitation. Strain or myocardial deformation differs from myocardial velocity in that it is not affected by tethering, i.e. being pulled along or affected by other myocardial segments (discussed later). Strain using TDI is more accurate in assessing regional wall motion than myocardial velocity alone. 106, 107 TDI velocity data has been used extensively for the detection of mechanical dyssynchrony with excellent results in predicting response to cardiac resynchronisation therapy in single centres with proficiency in this technique [108] [109] [110] [111] [112] ; however a recent multicentre trial (PROSPECT) using TDI dyssynchrony analysis has disappointing results indicating that this technique was subjective and needed expertise in image analysis. 113 Speckle tracking strain detection of dyssynchrony may overcome some of these reliability issues but this is yet to be verified on a larger scale. [114] [115] [116] [117] The key differences between tissue velocity, strain and strain rate are illustrated in Figure 14 . There are two myocardial "muscle bundles" shown in red (1) and green (2). In a normal heart the base of the heart descends to the apex during systole. The more basal muscle bundle (green) is pulled along by the more apical myocardium and therefore has a velocity even without contracting; however this green muscle bundle also has its own intrinsic contraction.
Because of this intrinsic contraction the velocity of the green muscle bundle is higher than that of the more apical red muscle bundle. To further illustrate this Figure 15 shows a heart with myocardial damage in the green muscle bundle. You can see that this damaged muscle bundle still has a velocity (this movement is known as tethering) however it is the same as the more apical red muscle bundle -indicating that there is no intrinsic contraction.
This velocity gradient from the base to the apex is how strain and strain rate are calculated from TDI data (Figure 16 ). Strain is calculated from the TDI data by comparing the velocity of two myocardial points and normalising this to the distance between these two points. Strain rate is simply the rate at which these two points move towards or away from each other. 118 Speckle tracking like tissue Doppler techniques also assess myocardial velocities and strain. This technique relies on tracking unique speckles found within the ultrasound image accentuated by harmonic imaging. These speckles are like unique fingerprints that can be tracked using complex algorithms to determine myocardial velocities or strain [119] [120] [121] [122] (Figure 17 ). However unlike Doppler techniques, they are angle independent and hence are not restricted to assess longitudinal function but can also assess circumferential and radial motion as well as rotation and twist of the myocardium (Figure 18 ). Speckle tracking requires high quality imaging with good spatial resolution so that the speckles are able to be tracked. The deformation (or strain) within the speckle fingerprint can be assessed directly rather than be converted from velocity information as the TDI technique does. [119] [120] [121] [122] Strain imaging using both TDI and speckle tracking has been shown to be of benefit in patients with ischaemic heart disease for detection of regional wall motion abnormalities [123] [124] [125] [126] [127] and in the detection of myocardial viability. 128, 129 Strain imaging has been shown to detect subclinical changes in patients with hypertrophic cardiomyopathy, [130] [131] [132] [133] [134] amyloid heart disease, [135] [136] [137] [138] chemotherapy cardiac toxicity 139 and may also assist in timing of surgery in valvular heart disease by detecting subtle changes prior to any decrease in ejection fraction (Figure 19 ). 
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Conclusions
Though these new and evolving techniques are very different, they have a common purpose which is to improve the diagnostic, prognostic and therapeutic utility of echo in patients with cardiac disease. While competing imaging modalities such as cardiac MRI and CT have made rapid progress, echocardiography particularly with these new techniques still remains the primary imaging modality in cardiology. 3D imaging for LV volumes and EF and contrast imaging in difficult patients have become standard practice in many echocardiography labs and continue to assist in daily clinical practice. Myocardial image with strain and strain rate however still remains within the realm of research at this stage but holds significant future promise. 
